Biocon share price
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Last close ₹323.50down ₹6.80 (2.06%)BSE ₹326.60
Share price at the NSE close on 23 Oct 2026. Previous close ₹330.30.
52-week range of traded prices to 23 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹52,721 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 106.4
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 58.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 8 May 2026
- 1.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.15%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 8 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 34,71,31952.6% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 5 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,336 Crdown 4.00%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹137 Crdown 31.12%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 3.2%
Revenue by year
Peak revenue ₹16,927 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 30 Oct | Dec 2024Filed 31 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 11 Nov | Dec 2025Filed 12 Feb | Mar 2026Filed 8 May | Jun 2026Filed 5 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Net profit | 27 | 81 | 459 | 89 | 133 | −52 | 199 | 137 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 0.8% | 2.1% | 10.4% | 2.3% | 3.1% | −1.2% | 4.4% | 3.2% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- BiosimilarsBiosimilars, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹10,431 Crup 15.68%60.2%
- CRDMOCRDMO, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,739 Cr21.6%
- GenericsGenerics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,168 Crup 4.99%18.3%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 63% of 1,843 trading days over the last 10 years.
LowestHighest
Its median46.9Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 2% of 1,803 trading days since Oct 2018.
LowestHighest
Its median4.5Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.18.2
At or below today's level on 30% of 1,803 trading days since Oct 2018.
LowestHighest
Its median21.5Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 50% of 2,475 trading days over the last 10 years.
LowestHighest
Its median0.15%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +5.8% | −71.8% | +274.7% | 0.1% |
| 3 years | +20.6% | −14.9% | +41.5% | 0.2% |
| 5 years | −2.2% | −17.4% | +18.0% | 0.3% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2026.
Mutual funds holding it
217 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 99 of the 131 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 68
- CutCut. Funds that held fewer shares than at the end of the month before.
- 63
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 81
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 5
| Fund | |||
|---|---|---|---|
 SBI Contra FundSBI Mutual Fund | 4,00,73,925 | 3.29% | ₹1,483.9 Cr |
| SBI Large & Midcap FundSBI Mutual Fund | 2,41,00,000 | 2.20% | ₹892.4 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 1,85,62,250 | 1.03% | ₹687.4 Cr |
| SBI Midcap FundSBI Mutual Fund | 1,55,98,584 | 2.48% | ₹577.6 Cr |
| SBI Balanced Advantage FundSBI Mutual Fund | 1,30,21,205 | 1.19% | ₹482.2 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 1,30,00,000 | 1.57% | ₹481.4 Cr |
 ICICI Prudential Focused FundICICI Prudential Mutual Fund | 1,24,62,450 | 2.69% | ₹461.5 Cr |
| SBI Multicap FundSBI Mutual Fund | 1,10,23,314 | 1.74% | ₹408.2 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 98,76,830 | 5.33% | ₹365.7 Cr |
| ICICI Prudential Multi Asset Allocation FundICICI Prudential Mutual Fund | 86,46,221 | 0.38% | ₹320.2 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Biocon in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹1.50 a share, year to Mar 2023.
| Ex-date | Type | Per share |
|---|---|---|
| 3 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 4 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 5 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 7 Jul 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 30 Jun 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 18 Jul 2019 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
14 Oct · Updates
10 Oct · General Updates
1 Oct · Options to purchase securities
Sep 2026
25 Sep · Updates
9 Sep · General Updates
Biocon share price by year
Each calendar year to 2025.Biocon share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 393.90 | +7.8% | 421.60 | 302.45 |
| 2024 | 365.35 | +46.3% | 391.20 | 245.75 |
| 2023 | 249.65 | −4.7% | 276.75 | 198.70 |
| 2022 | 261.85 | −28.2% | 407.25 | 260.80 |
| 2021 | 364.65 | −21.6% | 471.75 | 321.30 |
| 2020 | 465.40 | +58.5% | 483.60 | 252.40 |
| 2019 | 293.70 | −6.6% | 335.33 | 216.15 |
| 2018 | 314.53 | +17.1% | 354.20 | 267.40 |
| 2017 | 268.65 | +69.7% | 270.43 | 148.78 |
| 2016 | 158.31 | +83.3% | 168.03 | 73.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 330.30 | 330.90 | 318.40 | 323.50 | 323.03 | 34,71,319 | 52.6% |
| 22 Oct 2026 | 334.00 | 334.45 | 328.35 | 330.30 | 330.75 | 21,35,930 | 48.4% |
| 21 Oct 2026 | 342.00 | 344.00 | 330.75 | 335.00 | 335.10 | 24,52,266 | 53.4% |
| 19 Oct 2026 | 349.20 | 349.90 | 340.00 | 340.00 | 344.18 | 32,22,416 | 58.3% |
| 16 Oct 2026 | 352.60 | 353.00 | 348.00 | 349.20 | 349.90 | 18,76,294 | 60.3% |
| 15 Oct 2026 | 354.00 | 356.35 | 350.00 | 352.00 | 353.25 | 17,31,776 | 48.6% |
| 14 Oct 2026 | 353.00 | 353.00 | 347.00 | 350.60 | 350.93 | 33,75,381 | 63.5% |
| 13 Oct 2026 | 346.95 | 351.30 | 342.15 | 351.00 | 347.11 | 23,55,256 | 53.2% |
| 12 Oct 2026 | 348.10 | 351.80 | 345.10 | 346.35 | 348.07 | 26,32,161 | 54.4% |
| 9 Oct 2026 | 349.55 | 351.00 | 343.95 | 349.40 | 347.45 | 18,90,577 | 50.4% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 12 Jun 2019 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 15 Jun 2017 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
| 11 Sep 2008 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
About Biocon
Biocon Limited is a biopharmaceutical company headquartered in Bengaluru. It was incorporated in 1978. Its products business brings together biosimilars, insulins, complex generics and peptides, including GLP-1 therapies, on a single platform. Its services business is anchored by its listed subsidiary, Syngene International Limited.
The company reports its business in the Generics, Biosimilars and Novel Biologics segments, alongside Syngene. Syngene was incorporated in 1993 and is listed on the National Stock Exchange of India and BSE. It is a contract research, development and manufacturing organisation whose customers include pharmaceutical, biotechnology, animal health, consumer goods and specialty chemical companies. Under Novel Biologics, Biocon holds a 10.1% stake in Bicara Therapeutics, which is listed on Nasdaq.
Its biosimilars business has a commercial footprint in more than 120 countries. The company makes insulin at an integrated facility in Johor Bahru, Malaysia, and runs an oral solid dosage facility in Cranbury, New Jersey, in the United States. It has 39 subsidiaries and 1 joint venture, and its reported global operations cover both Biocon Limited and Syngene, together with their joint ventures, subsidiaries and acquisitions.
Biocon Biologics Limited, its biosimilars subsidiary, was incorporated in 2016. In 2023 the company integrated the global biosimilars business that it acquired from Viatris. In the year to March 2026 it decided to fully integrate Biocon Biologics by acquiring minority stakes, and from April 2026 it describes itself as a single organisation, OneBiocon. Kiran Mazumdar-Shaw is its Executive Chairperson.
- Legal name
- Biocon Limited
- NSE symbol
- BIOCON
- BSE code
- 532523
- ISIN
- INE376G01013
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Apr 2004
- Face value
- ₹5
- CIN
- L24234KA1978PLC003417
- Corporate identity number, the registrar of companies' code for it
In Nifty 200, BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index